Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/ADMA Biologics stays a Buy despite 40% drop, driven by strong Asceniv demand and revenue growth.
ADMA
$8.86
+$0.18 +2.07%

ADMA Biologics stays a Buy despite 40% drop, driven by strong Asceniv demand and revenue growth.

Analyst Insights
07 Apr 2026
Seeking Alpha
View Source
Bullish
pluang ai news

ADMA Biologics remains a Buy recommendation even after its stock fell 40%, supported by steady demand and premium pricing for its IVIG product Asceniv. The company shows strong fundamentals with a 51% year-over-year revenue increase and expects improvements in Days Sales Outstanding (DSO) by 2026, aided by a diversified distribution network and working capital focus. Management projects revenues exceeding $635 million in 2026 and at least $1.1 billion by 2029, acknowledging risks but seeing no immediate threats to Asceniv's outlook.

More News (ADMA)

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Deadline nears for investors to join class action lawsuits against BTGO, VIA, Z, and ADMA for alleged securities fraud.

Law Offices of Howard G. Smith reminds investors of approaching deadlines to file lead plaintiff motions in class action lawsuits against BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. These lawsuits allege the companies made f...

Market News
Bearish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App